Vetr upgraded shares of Celgene Corp. (NASDAQ:CELG) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. Vetr currently has $128.85 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on CELG. Argus restated a buy rating and set a $155.00 price target on shares of Celgene Corp. in a report on Wednesday, September 7th. Leerink Swann reaffirmed a market perform rating and set a $135.00 price objective on shares of Celgene Corp. in a research report on Monday, September 12th. Stifel Nicolaus reaffirmed a buy rating and set a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Piper Jaffray Cos. reaffirmed a buy rating on shares of Celgene Corp. in a research report on Tuesday, October 18th. Finally, Zacks Investment Research cut Celgene Corp. from a buy rating to a hold rating in a research report on Monday, August 8th. Four equities research analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $136.62.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) opened at 122.13 on Tuesday. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00. The firm has a 50-day moving average price of $108.88 and a 200-day moving average price of $106.73. The stock has a market cap of $94.68 billion, a price-to-earnings ratio of 46.38 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last posted its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.10. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.23 earnings per share. Equities analysts forecast that Celgene Corp. will post $5.92 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Celgene Corp. (CELG) Upgraded to Buy at Vetr Inc.” was published by Financial Market News and is owned by of Financial Market News. If you are viewing this news story on another publication, it was stolen and republished in violation of international copyright laws. The correct version of this news story can be read at http://www.financial-market-news.com/celgene-corp-celg-upgraded-to-buy-at-vetr-inc/1210421/.

In other news, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the transaction, the director now directly owns 72,142 shares in the company, valued at approximately $7,678,794.48. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Richard W. Barker sold 20,000 shares of the business’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the transaction, the director now owns 31,332 shares in the company, valued at $3,472,212.24. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Celgene Corp. by 0.8% in the second quarter. Vanguard Group Inc. now owns 47,833,717 shares of the biopharmaceutical company’s stock worth $4,717,840,000 after buying an additional 395,600 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Celgene Corp. by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 20,712,785 shares of the biopharmaceutical company’s stock worth $2,165,107,000 after buying an additional 471,143 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Celgene Corp. by 14.1% in the third quarter. Jennison Associates LLC now owns 15,921,002 shares of the biopharmaceutical company’s stock worth $1,664,222,000 after buying an additional 1,967,645 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Celgene Corp. by 3.4% in the third quarter. BlackRock Fund Advisors now owns 15,575,165 shares of the biopharmaceutical company’s stock worth $1,628,072,000 after buying an additional 508,334 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Celgene Corp. by 2.5% in the third quarter. Northern Trust Corp now owns 10,714,220 shares of the biopharmaceutical company’s stock worth $1,119,957,000 after buying an additional 261,176 shares in the last quarter. Institutional investors and hedge funds own 76.43% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.